Related Experiment Video
Updated: Aug 11, 2026

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
Published on: July 20, 2022
Disposition of ceftazidime after intraperitoneal administration in adolescent patients receiving continuous cycling
Laura L Sisterhen1, Cindy D Stowe, Hank C Farrar
1University of Arkansas for Medical Sciences College of Medicine, Arkansas Children's Hospital, Little Rock, AR 72202, USA.
Insights
Continuous intraperitoneal ceftazidime effectively treats peritonitis in children on continuous cycling peritoneal dialysis (CCPD). A maintenance dose without a loading dose achieved therapeutic antibiotic levels within 4 hours, persisting for 24 hours.
Area of Science:
- Pediatric Nephrology
- Infectious Diseases
- Pharmacokinetics
Background:
- Peritonitis is a common complication in pediatric continuous cycling peritoneal dialysis (CCPD).
- Current guidelines recommend combined intraperitoneal antibiotics for peritonitis treatment.
- The study investigated an alternative dosing strategy for ceftazidime.
Purpose of the Study:
- To evaluate the efficacy of a continuous maintenance dose of intraperitoneal ceftazidime without a loading dose.
- To determine if this regimen achieves adequate serum and dialysate concentrations for peritonitis treatment in pediatric CCPD patients.
Main Methods:
- Five pediatric patients on CCPD received continuous intraperitoneal ceftazidime (125 mg/L).
- Serum, dialysate, and urine samples were collected over 24 hours.
- Ceftazidime concentrations were quantified using high-performance liquid chromatography.
Main Results:
- Mean serum ceftazidime concentrations exceeded the minimum inhibitory concentration (MIC) within 4 hours and persisted.
- Mean dialysate ceftazidime concentrations also surpassed MIC levels within 4 hours.
- Serum bioavailability at 24 hours was 74% ± 6%.
Conclusions:
- A continuous maintenance dose of intraperitoneal ceftazidime is effective in treating peritonitis in pediatric CCPD patients.
- This dosing strategy achieves therapeutic antibiotic levels rapidly and sustains them for 24 hours.
- The findings support ceftazidime monotherapy without a loading dose for pediatric CCPD peritonitis.
Background:
Peritonitis is the single most common complication in children maintained on continuous cycling peritoneal dialysis (CCPD) and a significant cause of morbidity. Recent consensus guidelines for the treatment of peritonitis in children receiving peritoneal dialysis recommend the combined intraperitoneal administration of ceftazidime with either a first-generation cephalosporin or vancomycin. The objective of this study is to determine whether a continuous maintenance dose of intraperitoneal ceftazidime in the absence of a loading dose would maintain adequate serum and dialysate concentrations to be effective in the treatment of peritonitis.
Methods:
Five ambulatory patients on CCPD therapy were studied with continuous intraperitoneal administration of ceftazidime (125 mg/L). Blood, dialysate, and urine samples were collected at specified intervals during a 24-hour period. Ceftazidime concentrations were measured by using a high-performance liquid chromatography assay.
Results:
Mean serum concentrations at completion of the short rapid cycles and at 24 hours were 28.92 +/- 13.64 and 23.92 +/- 11.93 microg/mL, respectively. Serum bioavailability at 24 hours was 74% +/- 6%. Mean dialysate concentrations at completion of the short rapid cycles and at 24 hours were 87.43 +/- 19.18 and 32.06 +/- 6.27 microg/mL, respectively. All 5 patients achieved serum and dialysate ceftazidime concentrations greater than the mean inhibitory concentration within 4 hours.
Conclusion:
In adolescent patients on CCPD therapy, a continuous maintenance dose of intraperitoneal ceftazidime in the absence of a loading dose achieves serum and dialysate levels greater than the mean inhibitory concentration of sensitive organisms within 4 hours that persist for 24 hours.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Peritoneal Dialysis I: Introduction and Procedure
Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Acute Kidney Injury V: Interprofessional Care
